MedTrace Logo

Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir

NCT03247296 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-08-11

No results posted yet for this study

Summary

To evaluate the early detection of HCC in patients Taking Sofosbuvir and Daclatasvir.

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir 400 mg, Daclatasvir, Ribavirin

No intervention made this is an observational study to monitor the already existing protocols of the facility

Sponsors & Collaborators

  • MTI University

    lead OTHER

Principal Investigators

  • Nagwa A Sabri, Professor · Professor and Head of Clinical Pharmacy Department Faculty of Pharmacy Ain Shams University

  • Abd El Rahman El Naggar, Professor · Professor of clinicalpharmacology and Toxicology and Head of clinical pharmacy Department MTI University

  • Hasan A El Garem, Professor · Prof. Dr. of Endemic Medicine, hepatology, and gastroenterology Faculty of Medicine Cairo University

  • Aya M Esawy, Assistant Lecturer · Assistant Lecturer of clinical pharmacy at faculty of pharmacy MTI university

  • Sara M Zaki, Lecturer · Lecturer of clinical Pharmacy Faculty of pharmacy Ain-Shams University

  • May I Mehrez, Fellow · Fellow of Hepatology Internal Medicine Department (NHTMRI)

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2017-10-31
Completion
2017-11-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247296 on ClinicalTrials.gov